Results 21 to 30 of about 5,756 (231)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont +18 more
doaj +2 more sources
Profound Thrombocytopenia Associated With Administration of Eptifibatide [PDF]
Laboratory Medicine, 2007 Acute profound thrombocytopenia may be associated with the administration of eptifibatide, a glycoprotein antagonist. A case report of a 61-year-old male is presented. The reported incidence of acute profound thrombocytopenia associated with eptifibatide is 0.1% to 1.0% and usually occurs within 24 hours following therapy.
Gifford Lum, Paula Szuflad
openalex +2 more sources
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets [PDF]
Circulation, 2005 Background— Pretreatment is not the most common strategy practiced for clopidogrel administration in elective coronary stenting. Moreover, limited information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of ...
Paul A. Gurbel +5 more
openalex +4 more sources
Tibial bypass salvage with eptifibatide in a patient with thrombocythemia [PDF]
Journal of Vascular Surgery Cases, 2015 Early graft failure is a complex and challenging clinical condition faced by vascular surgeons performing infrainguinal bypass surgery. This case describes a patient with undiagnosed thrombocytosis undergoing urgent open revascularization for critical limb ischemia.
John Byrne +4 more
openalex +3 more sources
Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage
Case Reports in Critical Care, 2021 Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd +5 more
doaj +1 more source
Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]
Xin yixue, 2022 Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj +1 more source
A NEW HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE SEPARATION AND SIMULTANEOUS QUANTIFICATION OF EPTIFIBATIDE AND ITS IMPURITIES IN PHARMACEUTICAL INJECTION FORMULATION [PDF]
, 2021 Objective: The objective of the present study is to develop a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method for qualitative and quantitative determination of Eptifibatide and its impurities in bulk and ...
ANNA, VENKATESWARA RAO +2 more
core +3 more sources
Кардиоваскулярная терапия и профилактика, 2023 Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov +6 more
doaj +1 more source
Safety of Eptifibatide for Subcortical Stroke Progression [PDF]
Cerebrovascular Diseases, 2009 <i>Background:</i> There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation. <i>Methods:</i> We conducted a retrospective analysis of patients with subcortical stroke who ...
James C. Grotta +8 more
openaire +3 more sources
A Review of Clinical Trials with Eptifibatide in Cardiology [PDF]
Cardiovascular Drug Reviews, 2007 ABSTRACTGlycoprotein (GP) IIb/IIIa receptor antagonists inhibit the binding of ligands to activated platelet GP IIb/IIIa receptors and, therefore, prevent the formation of platelet thrombi. Additional antithrombin therapy should be given in connection with GP IIb/IIIa administration.
Uwe Zeymer, Harm Wienbergen
openaire +3 more sources